Current strategies in extending half-lives of therapeutic proteins
Rahela Zaman(University of Michigan), Ezharul Hoque Chowdhury(Monash University Malaysia), Iekhsan Othman(Monash University Malaysia), Rowshan Ara Islam(Monash University Malaysia), Anuar Zaini(Monash University Malaysia), Chooi Yeng Lee(Monash University Malaysia), Nabilah Ibnat(Monash University Malaysia)
Cited by 285
Related Papers
HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy, and Cognitive Dysfunction
|Frontiers in Neuroscience|2018|318
Impact of HMGB1, RAGE, and TLR4 in Alzheimer’s Disease (AD): From Risk Factors to Therapeutic Targeting
|Cells|2020|257
Mangrove rare actinobacteria: taxonomy, natural compound, and discovery of bioactivity
|Frontiers in Microbiology|2015|178
Enlightening the role of high mobility group box 1 (HMGB1) in inflammation: Updates on receptor signalling
|European Journal of Pharmacology|2019|175
Mechanism of Apoptosis Induced by Curcumin in Colorectal Cancer
|International Journal of Molecular Sciences|2019|166